Bottom line
Survodutide is a dual glucagon/GLP-1 receptor agonist in late-stage clinical development by Boehringer Ingelheim. Unlike tirzepatide (which pairs GLP-1 with GIP), survodutide pairs GLP-1 with glucagon — a hormone traditionally associated with raising blood sugar. The counterintuitive combination produces:
- Significant weight loss — up to 18-19% total body weight
loss at 46 weeks in Phase 2 trials
- Dramatic reduction in liver fat — a finding that
positions it as a potential treatment for MASH (metabolic dysfunction-associated steatohepatitis, formerly NASH), one of the largest unmet needs in hepatology
- Improved metabolic markers — HbA1c, lipids, liver
enzymes
Survodutide is not yet FDA-approved. Phase 3 trials for both obesity and MASH are ongoing, with potential approval timelines in 2027-2028.
Why glucagon?
Glucagon seems like an odd choice for an obesity drug — it raises blood sugar, which is the opposite of what you want in diabetes. But glucagon does several other things that are therapeutically interesting:
1. Increases energy expenditure. Glucagon activates thermogenesis (calorie burning) in brown adipose tissue and the liver. This means survodutide may increase the calories you burn at rest — a different mechanism from GLP-1 drugs that primarily reduce the calories you consume.
2. Mobilizes liver fat. Glucagon promotes hepatic lipid oxidation — the burning of fat stored in the liver. For patients with fatty liver disease (NAFLD/MASH), this is precisely the mechanism needed. GLP-1s alone reduce liver fat somewhat through weight loss. Glucagon co-agonism may reduce liver fat more directly and substantially.
3. Reduces appetite. Glucagon receptor activation in the brain contributes to satiety, complementing the GLP-1 appetite suppression.
The GLP-1 component offsets glucagon's blood-sugar-raising effect by enhancing glucose-dependent insulin secretion. The net glycemic effect in trials has been neutral to beneficial.
Phase 2 results
The Phase 2 trial data for survodutide, published in peer-reviewed journals:
Obesity (ACHIEVE trial):
- 46 weeks of treatment
- Survodutide at 4.8 mg weekly: approximately 14.9% body
weight loss
- Survodutide at 6.0 mg weekly: approximately 18.7% body
weight loss
- Placebo: approximately 2.1%
- The 18.7% figure at 46 weeks is notable because it
approaches the weight loss seen with tirzepatide at 72 weeks in a shorter timeframe
MASH/liver disease:
- Survodutide produced statistically significant reductions
in liver fat (measured by MRI-PDFF) compared to placebo
- Meaningful improvement in MASH histology scores
- Reduction in liver fibrosis markers
- These liver-specific results are what make survodutide
unique in the GLP-1 adjacent class — no other drug in this family has shown comparable liver effects
Side effects:
- GI events (nausea, diarrhea, vomiting) were the most
common, consistent with the GLP-1 class
- Rates were slightly higher than pure GLP-1 drugs,
likely due to the glucagon component
- Heart rate increases were observed (a known glucagon
effect), though clinically modest
- Discontinuation rates due to adverse events were higher
than semaglutide trials, suggesting tolerability may be a challenge at higher doses
Where it fits in the pipeline
The current GLP-1/incretin pipeline has several categories:
Single GLP-1 agonists: semaglutide, orforglipron (oral) — established, deep safety data, the current standard.
Dual GLP-1/GIP agonists: tirzepatide — the current weight-loss leader among approved drugs.
Triple agonists (GLP-1/GIP/glucagon): retatrutide (Lilly) — the farthest along, with Phase 3 data expected in 2026-2027. Has produced the largest weight loss numbers in the class (up to 24% at 48 weeks in Phase 2).
Dual GLP-1/glucagon agonists: survodutide (Boehringer), pemvidutide (Altimmune) — differentiated by the liver fat effect and the energy expenditure mechanism.
Amylin-based combinations: cagrilintide + semaglutide (CagriSema, Novo Nordisk) — Phase 3 ongoing, targeting the amylin pathway alongside GLP-1.
Survodutide's niche is clearest for patients with both obesity and MASH. If the Phase 3 MASH data confirms the Phase 2 signal, survodutide could become the first approved pharmacotherapy specifically for MASH — a market that has been waiting for an effective drug for years.
What this means for you
Survodutide is not available today. It's a pipeline drug worth watching for two reasons:
If you have fatty liver disease (NAFLD/MASH): this may be the first drug that directly addresses liver fat through a mechanism beyond weight loss alone. Current GLP-1s help (weight loss reduces liver fat), but survodutide's glucagon component may produce faster and larger liver-fat improvements.
If you're interested in the next generation of obesity drugs: survodutide represents a different approach — not just reducing food intake but also increasing energy expenditure. If the Phase 3 data holds, it adds a genuinely new tool to the obesity medicine toolkit.
For now, the approved options — semaglutide, tirzepatide, orforglipron — are the drugs to discuss with your prescriber. But if liver health is a significant part of your clinical picture, ask about emerging options and whether clinical trial participation might be appropriate.